359 related articles for article (PubMed ID: 30196794)
1. Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting.
Bruijning-Verhagen P; van Dongen JAP; Verberk JDM; Pijnacker R; van Gaalen RD; Klinkenberg D; de Melker HE; Mangen MJ
BMC Med; 2018 Sep; 16(1):168. PubMed ID: 30196794
[TBL] [Abstract][Full Text] [Related]
2. Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination.
Bruijning-Verhagen P; Mangen MJ; Felderhof M; Hartwig NG; van Houten M; Winkel L; de Waal WJ; Bonten MJ
BMC Med; 2013 Apr; 11():112. PubMed ID: 23622110
[TBL] [Abstract][Full Text] [Related]
3. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of childhood rotavirus vaccination in Germany.
Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
[TBL] [Abstract][Full Text] [Related]
5. Beyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in Australia.
Reyes JF; Wood JG; Beutels P; Macartney K; McIntyre P; Menzies R; Mealing N; Newall AT
Vaccine; 2017 Jan; 35(2):345-352. PubMed ID: 27916411
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.
Tilson L; Jit M; Schmitz S; Walsh C; Garvey P; McKeown P; Barry M
Vaccine; 2011 Oct; 29(43):7463-73. PubMed ID: 21821085
[TBL] [Abstract][Full Text] [Related]
8. Health impact and cost-effectiveness of a domestically-produced rotavirus vaccine in India: A model based analysis.
Rose J; Homa L; Meropol SB; Debanne SM; Bielefeld R; Hoyen C; Singer ME
PLoS One; 2017; 12(11):e0187446. PubMed ID: 29099848
[TBL] [Abstract][Full Text] [Related]
9. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis.
Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N
Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness estimates of vaccination against rotavirus in Piedmont, Italy.
Gualano MR; Thomas R; Gili R; Scaioli G; Voglino G; Zotti C
J Infect Public Health; 2018; 11(6):867-872. PubMed ID: 30078657
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Rotavirus Vaccination in France-Accounting for Indirect Protection.
Yamin D; Atkins KE; Remy V; Galvani AP
Value Health; 2016; 19(6):811-819. PubMed ID: 27712709
[TBL] [Abstract][Full Text] [Related]
12. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam.
Fischer TK; Anh DD; Antil L; Cat ND; Kilgore PE; Thiem VD; Rheingans R; Tho le H; Glass RI; Bresee JS
J Infect Dis; 2005 Nov; 192(10):1720-6. PubMed ID: 16235169
[TBL] [Abstract][Full Text] [Related]
13. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
[TBL] [Abstract][Full Text] [Related]
15. Potential intussusception risk versus health benefits from rotavirus vaccination in Latin America.
Desai R; Parashar UD; Lopman B; de Oliveira LH; Clark AD; Sanderson CF; Tate JE; Matus CR; Andrus JK; Patel MM
Clin Infect Dis; 2012 May; 54(10):1397-405. PubMed ID: 22431803
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care'' disease impact in Belgium.
Bilcke J; Van Damme P; Beutels P
Med Decis Making; 2009; 29(1):33-50. PubMed ID: 18948433
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran.
Javanbakht M; Moradi-Lakeh M; Yaghoubi M; Esteghamati A; Mansour Ghanaie R; Mahmoudi S; Shamshiri AR; Zahraei SM; Baxter L; Shakerian S; Chaudhri I; Fleming JA; Munier A; Baradaran HR
Vaccine; 2015 May; 33 Suppl 1():A192-200. PubMed ID: 25919160
[TBL] [Abstract][Full Text] [Related]
18. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule.
Milne RJ; Grimwood K
Value Health; 2009 Sep; 12(6):888-98. PubMed ID: 19490550
[TBL] [Abstract][Full Text] [Related]
19. Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis.
Verguet S; Murphy S; Anderson B; Johansson KA; Glass R; Rheingans R
Vaccine; 2013 Oct; 31(42):4902-10. PubMed ID: 23871824
[TBL] [Abstract][Full Text] [Related]
20. Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia.
Loganathan T; Ng CW; Lee WS; Hutubessy RCW; Verguet S; Jit M
Health Policy Plan; 2018 Mar; 33(2):204-214. PubMed ID: 29228339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]